Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 12 systematic review(s)/meta-analysis(es). ^[1-12]
• Relapse Rates and Disease Activity: Dimethyl fumarate demonstrated a moderate relapse rate reduction over 24 months (RR (relative risk) 0.62, 95% CI (confidence interval) 0.55 to 0.70), with greater efficacy when DMTs were continued into early pregnancy rather than discontinued. Cladribine tablets outperformed dimethyl fumarate in achieving NEDA-3 (OR (odds ratio) =1.76, 95% CrI: 1.02-3.03).
• Disability Progression: Ozanimod showed improved outcomes over dimethyl fumarate for confirmed disability progression (CDP) at 3 months (HR (hazard ratio) 0.67, 95% CI 0.53-0.86); however, no significant difference was observed at 6 months. Natalizumab was more effective for high-risk patients, while dimethyl fumarate showed effectiveness in low-risk patients.
• Treatment Adherence: Dimethyl fumarate demonstrated a high adherence rate, with approximately 78.5% of patients maintaining adherence at one year (MPR ≥80%).
• Comparative Efficacy with Other Oral DMDs: Dimethyl fumarate showed a slightly lower relapse risk than teriflunomide (RR = 0.92) and demonstrated moderate effectiveness compared to fingolimod, which exhibited superior MRI and ARR outcomes.
• Dimethyl fumarate displayed a non-inferior risk of serious adverse events (SAEs) compared to placebo (RR 0.79, 95% CI 0.67 to 0.93).
• Dimethyl fumarate was associated with a higher risk of treatment discontinuation due to adverse events relative to teriflunomide (RR 1.07, p = 0.007), with commonly reported adverse events including gastrointestinal disturbances and flushing.
• Dimethyl fumarate and glatiramer acetate had a favorable safety profile, showing lower withdrawal rates due to adverse events compared to interferon beta-1a and fingolimod.
• Evidence indicates dimethyl fumarate shows protective effects against relapses when used preconception and during early pregnancy, is effective for low-risk patients compared to high-risk patients who benefit more from natalizumab, demonstrates varying relapse risk reductions in younger and treatment-naive patients, does not increase risk of SARS-CoV-2 infection or severe COVID-19, and is associated with PML cases where younger age and lower JCV viral load present favorable prognostic factors.